Myeongmun Pharmaceutical (017180) has 58 disclosed insider purchases and 0 disclosed disposals on record, filed by 7 distinct insiders. Together those filings cover ₩884M ($614K) in reported transaction value. The earliest filing StockDrifts holds for Myeongmun Pharmaceutical is dated 2023-07-13; the most recent is 2026-07-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +10.11%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 3.6K | ₩1,253 | +0.2% | ₩5M ($3K) |
| 2026-08-04 | BUY | Market Buy | 양환태 Hwantae Yang | Managing Director | 44 | ₩1,136 | +1.9% | ₩50K ($35) |
| 2026-08-03 | BUY | Market Buy | 권용진 Yongjin Kwon | moving | 2.5K | ₩1,083 | +6.9% | ₩3M ($2K) |
| 2026-08-03 | BUY | Market Buy | 양환태 Hwantae Yang | Managing Director | 2.7K | ₩1,083 | +6.9% | ₩3M ($2K) |
| 2026-07-01 | SELL | 증여 | 정준일 Jeong Jun-il | Managing Director | -119.0K | ₩1,282 | +1.0% | ₩153M ($106K) |
| 2026-07-01 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 3.5K | ₩1,282 | -1.0% | ₩4M ($3K) |
| 2026-06-30 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 1.4K | ₩1,272 | -0.2% | ₩2M ($1K) |
| 2026-06-29 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 3.6K | ₩1,270 | -0.1% | ₩5M ($3K) |
| 2026-06-11 | BUY | Market Buy | 양환태 Hwantae Yang | Managing Director | 5.4K | - | - | - |
| 2026-04-28 | BUY | 자사주상여금 | 유정권 Yoo Jeong-kwon | Managing Director | 2.7K | ₩1,756 | +1.8% | ₩5M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 장윤수 Jang Yunsu | Managing Director | 7.4K | ₩1,756 | +1.8% | ₩13M ($9K) |
| 2026-04-28 | BUY | 자사주상여금 | 이장호 Jangho Lee | Managing Director | 2.7K | ₩1,756 | +1.8% | ₩5M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 임기섭 Lim Lim Seop | moving | 2.5K | ₩1,756 | +1.8% | ₩4M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 이경희 Kyunghee Lee | moving | 2.5K | ₩1,756 | +1.8% | ₩4M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 양환태 Hwantae Yang | moving | 2.7K | ₩1,756 | +1.8% | ₩5M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 권용진 Yongjin Kwon | moving | 2.5K | ₩1,756 | +1.8% | ₩4M ($3K) |
| 2026-04-28 | BUY | 자사주상여금 | 이영미 Youngmi Lee | Managing Director | 2.8K | ₩1,756 | +1.8% | ₩5M ($3K) |
| 2026-02-10 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 1.7K | ₩1,817 | +6.4% | ₩3M ($2K) |
| 2026-02-05 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 1.7K | ₩1,791 | +7.9% | ₩3M ($2K) |
| 2026-02-04 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 4.6K | ₩1,761 | +9.8% | ₩8M ($6K) |
| 2026-02-03 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 12.8K | ₩1,777 | +8.8% | ₩23M ($16K) |
| 2026-02-02 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 2.2K | ₩1,731 | +11.7% | ₩4M ($3K) |
| 2026-01-30 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 5.0K | ₩1,790 | +8.0% | ₩9M ($6K) |
| 2026-01-08 | BUY | Market Buy | 이경희 Kyunghee Lee | moving | 10.0K | ₩1,810 | +6.8% | ₩18M ($13K) |
| 2026-01-06 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 9.0K | ₩1,796 | +7.6% | ₩16M ($11K) |
| 2025-12-24 | BUY | Market Buy | 이경희 Kyunghee Lee | moving | 28.2K | ₩1,823 | +6.0% | ₩51M ($36K) |
| 2025-12-24 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 4.5K | ₩1,823 | +6.0% | ₩8M ($6K) |
| 2025-12-23 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 5.5K | ₩1,850 | +4.5% | ₩10M ($7K) |
| 2025-12-23 | BUY | Market Buy | 이경희 Kyunghee Lee | moving | 8.8K | ₩1,850 | +4.5% | ₩16M ($11K) |
| 2025-12-18 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 5.5K | ₩1,850 | +4.5% | ₩10M ($7K) |
| 2025-12-17 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 4 | ₩1,945 | -0.6% | ₩8K ($5) |
| 2025-12-15 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 10.6K | ₩1,826 | +5.9% | ₩19M ($13K) |
| 2025-12-11 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 10.0K | ₩1,887 | +2.4% | ₩19M ($13K) |
| 2025-12-10 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 10.1K | ₩1,800 | +7.4% | ₩18M ($13K) |
| 2025-12-09 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 39.9K | ₩1,827 | +5.8% | ₩73M ($51K) |
| 2025-12-08 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 10.0K | ₩1,820 | +6.2% | ₩18M ($13K) |
| 2025-12-04 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 9.0K | ₩1,705 | +13.4% | ₩15M ($11K) |
| 2025-12-03 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 14.0K | ₩1,706 | +13.3% | ₩24M ($17K) |
| 2025-12-02 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 3.0K | ₩1,709 | +13.1% | ₩5M ($4K) |
| 2025-12-02 | BUY | Market Buy | 이경희 Kyunghee Lee | moving | 7.9K | ₩1,709 | +13.1% | ₩14M ($9K) |
| 2025-12-01 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 3.0K | ₩1,712 | +12.9% | ₩5M ($4K) |
| 2025-11-28 | BUY | Market Buy | 정준일 Jeong Jun-il | Managing Director | 985 | ₩1,712 | +12.9% | ₩2M ($1K) |
| 2025-11-25 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 125 | ₩1,709 | +13.1% | ₩214K ($148) |
| 2025-11-24 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 2.7K | ₩1,735 | +11.4% | ₩5M ($3K) |
| 2025-11-21 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 5.0K | ₩1,764 | +9.6% | ₩9M ($6K) |
| 2025-11-20 | BUY | Market Buy | 배철한 Bae Cheol-han | CEO/President | 17.2K | ₩1,782 | +8.5% | ₩31M ($21K) |
| 2025-11-20 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 3.3K | ₩1,782 | +8.5% | ₩6M ($4K) |
| 2025-11-19 | BUY | Market Buy | 배철한 Bae Cheol-han | CEO/President | 20.0K | ₩1,758 | +9.9% | ₩35M ($24K) |
| 2025-11-19 | BUY | Market Buy | 임기섭 Lim Lim Seop | moving | 2.5K | ₩1,758 | +9.9% | ₩4M ($3K) |
| 2025-11-18 | BUY | Market Buy | 배철한 Bae Cheol-han | CEO/President | 20.0K | ₩1,731 | +11.7% | ₩35M ($24K) |
Showing the 50 most recent of 71 filings.
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Myeongmun Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.